Krystal Biotech Inc reports results for the quarter ended in December - Earnings Summary

Krystal Biotech

26/02/2024 14:31

* Krystal Biotech Inc  KRYS.OQ  reported quarterly adjusted
earnings of 30 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-1.25.  The mean expectation of
nine analysts for the quarter was for a loss of 38 cents per
share. Wall Street expected results to range from -95 cents
to -1 cents per share.
    * Revenue was $42.14 million​; analysts expected $28.61
million. 
    * Krystal Biotech Inc's reported EPS for the quarter was 30
cents​.
    * The company reported quarterly net income of $8.69
million.
    * Krystal Biotech Inc shares had fallen by 10.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 10.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Krystal Biotech
Inc is $156.50 
This summary was machine generated from LSEG data February 26 at
02:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.38          0.30           Beat
 Sep. 30 2023      -0.29          -0.69          Missed
 Jun. 30 2023      -0.74          -1.25          Missed
 Mar. 31 2023      -1.44          -1.76          Missed